Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment

Shashi Raj, Vivian I. Franco, Steven E Lipshultz

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Anthracyclines have been widely used in children and adults to treat hematologic malignancies, soft-tissue sarcomas, and solid tumors. However, anthracyclines come with both short- and long-term cardiotoxic effects, ranging from occult changes in myocardial structure and function to severe cardiomyopathy and heart failure that may result in cardiac transplantation or death. Here, we review the progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies, such as dexrazoxane; and improving cardioprotection with agents such as liposomal and pegylated doxorubicin. Despite this increased understanding, preventing drug-induced cardiotoxicity while maintaining oncologic efficacy to achieve the highest quality of life over a lifespan remain cornerstones of successful anthracycline chemotherapy during childhood.

Original languageEnglish
Article number315
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume16
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Anthracyclines
Dexrazoxane
Hematologic Neoplasms
Heart Transplantation
Therapeutics
Cardiomyopathies
Sarcoma
Molecular Biology
Heart Failure
Quality of Life
Drug Therapy
Cardiotoxicity
Pharmaceutical Preparations
Neoplasms

Keywords

  • Anthracycline
  • Cardiomyopathy
  • Childhood cancer survivor
  • Dexrazoxane
  • Left ventricular dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anthracycline-induced cardiotoxicity : A review of pathophysiology, diagnosis, and treatment. / Raj, Shashi; Franco, Vivian I.; Lipshultz, Steven E.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 16, No. 6, 315, 01.01.2014.

Research output: Contribution to journalArticle

@article{8285cc2edea04ac7bc6a7d3fbb5ea408,
title = "Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment",
abstract = "Anthracyclines have been widely used in children and adults to treat hematologic malignancies, soft-tissue sarcomas, and solid tumors. However, anthracyclines come with both short- and long-term cardiotoxic effects, ranging from occult changes in myocardial structure and function to severe cardiomyopathy and heart failure that may result in cardiac transplantation or death. Here, we review the progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies, such as dexrazoxane; and improving cardioprotection with agents such as liposomal and pegylated doxorubicin. Despite this increased understanding, preventing drug-induced cardiotoxicity while maintaining oncologic efficacy to achieve the highest quality of life over a lifespan remain cornerstones of successful anthracycline chemotherapy during childhood.",
keywords = "Anthracycline, Cardiomyopathy, Childhood cancer survivor, Dexrazoxane, Left ventricular dysfunction",
author = "Shashi Raj and Franco, {Vivian I.} and Lipshultz, {Steven E}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11936-014-0315-4",
language = "English",
volume = "16",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Anthracycline-induced cardiotoxicity

T2 - A review of pathophysiology, diagnosis, and treatment

AU - Raj, Shashi

AU - Franco, Vivian I.

AU - Lipshultz, Steven E

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Anthracyclines have been widely used in children and adults to treat hematologic malignancies, soft-tissue sarcomas, and solid tumors. However, anthracyclines come with both short- and long-term cardiotoxic effects, ranging from occult changes in myocardial structure and function to severe cardiomyopathy and heart failure that may result in cardiac transplantation or death. Here, we review the progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies, such as dexrazoxane; and improving cardioprotection with agents such as liposomal and pegylated doxorubicin. Despite this increased understanding, preventing drug-induced cardiotoxicity while maintaining oncologic efficacy to achieve the highest quality of life over a lifespan remain cornerstones of successful anthracycline chemotherapy during childhood.

AB - Anthracyclines have been widely used in children and adults to treat hematologic malignancies, soft-tissue sarcomas, and solid tumors. However, anthracyclines come with both short- and long-term cardiotoxic effects, ranging from occult changes in myocardial structure and function to severe cardiomyopathy and heart failure that may result in cardiac transplantation or death. Here, we review the progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies, such as dexrazoxane; and improving cardioprotection with agents such as liposomal and pegylated doxorubicin. Despite this increased understanding, preventing drug-induced cardiotoxicity while maintaining oncologic efficacy to achieve the highest quality of life over a lifespan remain cornerstones of successful anthracycline chemotherapy during childhood.

KW - Anthracycline

KW - Cardiomyopathy

KW - Childhood cancer survivor

KW - Dexrazoxane

KW - Left ventricular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84901262265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901262265&partnerID=8YFLogxK

U2 - 10.1007/s11936-014-0315-4

DO - 10.1007/s11936-014-0315-4

M3 - Article

AN - SCOPUS:84901262265

VL - 16

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 6

M1 - 315

ER -